Physician profile
Manuel Mesirow
NPI 1396711503
$4,173.16
in general payments reported to CMS, 2019-2025
29 companies · $713 in 2025
The $713 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $963 · 2020: $314 · 2021: $114 · 2022: $554 · 2023: $670 · 2024: $844 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,181 · Education: $45.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,181.28 |
| Education | $45.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,187.61 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $660.30 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $368.05 | 2019-2025 | Dupixent |
| Genzyme Corporation | $245.81 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $226.49 | 2019-2025 | |
| Pfizer INC. | $221.85 | 2019-2025 | |
| Janssen Biotech, INC. | $218.31 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $134.90 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $134.63 | 2019-2024 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $121.85 | 2023-2025 | Nemluvio |
| Dermavant Sciences, INC. | $95.34 | 2023-2024 | Vtama |
| Incyte Corporation | $51.98 | 2021-2024 | Opzelura |
| Celgene Corporation | $41.86 | 2019 | |
| Biofrontera INC. | $40.90 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Leo Pharma INC. | $40.08 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $38.74 | 2019-2020 | |
| Genentech USA, INC. | $38.23 | 2019 | |
| Organon LLC | $34.18 | 2024-2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $32.10 | 2023-2024 | Zoryve |
| Dermira, INC. | $31.04 | 2019 | |
| Verrica Pharmaceuticals INC. | $28.97 | 2025 | Ycanth |
| Fresenius Kabi USA, LLC | $28.87 | 2023 | Idacio |
| Helsinn Therapeutics (U.S.), INC. | $27.99 | 2019 | |
| Mayne Pharma Commercial LLC | $27.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.84 | 2023 | Sotyktu |
| Epi Health, LLC | $22.17 | 2022 | |
| Dusa Pharmaceuticals, INC. | $18.72 | 2019 | |
| Aclaris Therapeutics, INC. | $17.37 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Mesirow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.